Page last updated: 2024-10-16

carbamates and Allodynia

carbamates has been researched along with Allodynia in 44 studies

Research Excerpts

ExcerptRelevanceReference
"To determine the effects of retigabine and flupirtine on pain behavior associated with monosodium urate (MSU)-induced gout arthritis."7.96Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain. ( Huo, B; Jin, L; Li, H; Liu, R; Liu, S; Tang, L; Wang, Y; Yang, T; Zhang, F; Zhao, X, 2020)
"Given that the pharmacological or genetic inactivation of fatty acid amide hydrolase (FAAH) counteracts pain and inflammation, and on the basis of the established involvement of transient receptor potential vanilloid type-1 (TRPV1) channels in inflammatory pain, we tested the capability of a dual FAAH/TRPV1 blocker, N-arachidonoyl-serotonin (AA-5-HT), to relieve oedema and pain in a model of acute inflammation, and compared its efficacy with that of a single FAAH inhibitor (URB597) or TRPV1 antagonist (capsazepine)."7.76The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. ( Bettoni, I; Comelli, F; Costa, B; Di Marzo, V; Giagnoni, G; Petrosino, S, 2010)
"Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone."5.39Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. ( Burlakova, N; Coicou, L; Harding-Rose, C; Holman, M; Khasabova, IA; Morse, T; Seybold, VS; Simone, DA, 2013)
"N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents."5.34New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007)
"To determine the effects of retigabine and flupirtine on pain behavior associated with monosodium urate (MSU)-induced gout arthritis."3.96Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain. ( Huo, B; Jin, L; Li, H; Liu, R; Liu, S; Tang, L; Wang, Y; Yang, T; Zhang, F; Zhao, X, 2020)
"JZL195 and the cannabinoid receptor agonist WIN55212 produced dose-dependent reductions in CCI-induced mechanical and cold allodynia, plus side effects including motor incoordination, catalepsy and sedation."3.83Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model. ( Adamson Barnes, NS; Kazantzis, NP; Mitchell, VA; Vaughan, CW, 2016)
" administration of morphine and the selective MAGL inhibitor 2,5-dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)piperazine-1-carboxylate (MJN110) were tested alone and in combination at equieffective doses for reversal of CCI-induced mechanical allodynia and thermal hyperalgesia."3.83The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. ( Abdullah, RA; Akbarali, H; Banks, ML; Cravatt, BF; Dewey, WL; Grim, TW; Lichtman, AH; Mustafa, MA; Niphakis, MJ; Poklis, JL; Wilkerson, JL; Wise, LE, 2016)
" Two distinct FAAH inhibitory compounds, URB597 and PF-3845 were tested, and contrasted with standard antinociceptive gabapentin or vehicle treatment, for attenuation of tactile allodynia, cold allodynia, and mechanical hyperalgesia."3.81Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy. ( Jergova, S; Nasirinezhad, F; Pearson, JP; Sagen, J, 2015)
"The pharmacological inhibition of anandamide (AEA) hydrolysis by fatty acid amide hydrolase (FAAH) attenuates pain in animal models of osteoarthritis (OA) but has failed in clinical trials."3.81A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis. ( Binkowski, M; Czaja, M; Di Marzo, V; Kolosowska, N; Makuch, W; Malek, N; Morera, E; Mrugala, M; Przewlocka, B; Starowicz, K, 2015)
" In the present study, we conducted a comparative characterization of the effects of the newly identified brain-impermeant FAAH inhibitor, URB937 ([3-(3-carbamoylphenyl)-4-hydroxy-phenyl] N-cyclohexylcarbamate), in various rodent models of acute and persistent pain."3.78Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions. ( Armirotti, A; Bandiera, T; Bertorelli, R; Colombano, G; Moreno-Sanz, G; Piomelli, D; Reggiani, A; Sasso, O; Scarpelli, R, 2012)
"Given that the pharmacological or genetic inactivation of fatty acid amide hydrolase (FAAH) counteracts pain and inflammation, and on the basis of the established involvement of transient receptor potential vanilloid type-1 (TRPV1) channels in inflammatory pain, we tested the capability of a dual FAAH/TRPV1 blocker, N-arachidonoyl-serotonin (AA-5-HT), to relieve oedema and pain in a model of acute inflammation, and compared its efficacy with that of a single FAAH inhibitor (URB597) or TRPV1 antagonist (capsazepine)."3.76The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. ( Bettoni, I; Comelli, F; Costa, B; Di Marzo, V; Giagnoni, G; Petrosino, S, 2010)
"The analgesic and anti-hyperalgesic effects of cannabinoid- and vanilloid-like compounds, plus the fatty acid amide hydrolase (FAAH) inhibitor Cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597), and acetaminophen, were evaluated in the phenyl-p-quinone (PPQ) pain model, using different routes of administration in combination with opioid and cannabinoid receptor antagonists."3.73Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. ( Cichewicz, DL; Haller, VL; Welch, SP, 2006)
"The decreased hyperalgesia was associated with a reduction in CGRP and cytokine gene expression levels in central and peripheral structures and reduced CGRP serum levels."1.62Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine. ( Demartini, C; Francavilla, M; Greco, R; Tassorelli, C; Zanaboni, AM, 2021)
"Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients."1.56Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020)
"Paclitaxel produced mechanical and cold allodynia without altering nestlet shredding or marble burying behaviors."1.48Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. ( Hohmann, AG; Iyer, V; Makriyannis, A; Saberi, SA; Slivicki, RA; Vemuri, VK, 2018)
"Chronic pain and hyperalgesia, as well as pain resulting from episodes of vaso-occlusion, are characteristic features of sickle cell disease (SCD) and are difficult to treat."1.46Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis. ( Gupta, K; Simone, DA; Uhelski, ML, 2017)
"SA-57 dose-dependently reversed mechanical allodynia in the constriction injury (CCI) of the sciatic nerve model of neuropathic pain and carrageenan inflammatory pain model."1.46The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. ( Abdullah, RA; Cabrera, R; Cravatt, BF; Ghosh, S; Lichtman, AH; Maldonado, RL; Mustafa, M; Niphakis, MJ; Wilkerson, JL, 2017)
"Remarkably, the long-lasting widespread hyperalgesia induced by combining CUS and NGF was effectively reduced by URB597, but not by JZL184."1.42Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain. ( Bindila, L; Hoheisel, U; Lerner, R; Lomazzo, E; Lutz, B; Remmers, F; Schwitter, C, 2015)
"Using a rat model of bone cancer pain based on intratibial injection of MRMT-1 tumor cells, we observed a significant increase in C-fiber responses of dorsal horn WDR neurons in the MRMT-1 injected rats, indicating sensitization of spinal WDR neurons in bone cancer rats."1.42Suppression of KCNQ/M (Kv7) potassium channels in the spinal cord contributes to the sensitization of dorsal horn WDR neurons and pain hypersensitivity in a rat model of bone cancer pain. ( Cai, J; Fang, D; Li, S; Liu, XD; Ren, J; Xing, GG, 2015)
"We found that nitroglycerin-induced mechanical allodynia and neuronal activation of the trigeminal nucleus were completely abolished in FAAH-deficient mice."1.42Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice. ( Markert, A; Nozaki, C; Zimmer, A, 2015)
"Orofacial cold hyperalgesia was induced in rats either by the administration of oxaliplatin or by infraorbital nerve chronic constrictive injury."1.42KCNQ channels in nociceptive cold-sensing trigeminal ganglion neurons as therapeutic targets for treating orofacial cold hyperalgesia. ( Abd-Elsayed, AA; Gu, JG; Ikeda, R; Jia, Z; Li, M; Ling, J; Zuo, X, 2015)
"Spinal AEA reduces neuropathic pain by acting at both cannabinoid CB1 receptors and transient receptor potential vanilloid-1 (TRPV1) channels."1.39Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. ( Cristino, L; De Petrocellis, L; Di Marzo, V; Korostynski, M; Makuch, W; Malek, N; Petrosino, S; Przewlocka, B; Slezak, M; Starowicz, K; Zychowska, M, 2013)
"Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone."1.39Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. ( Burlakova, N; Coicou, L; Harding-Rose, C; Holman, M; Khasabova, IA; Morse, T; Seybold, VS; Simone, DA, 2013)
"Bone cancer pain has a strong impact on the quality of life of patients, but is difficult to treat."1.39Suppression of KCNQ/M (Kv7) potassium channels in dorsal root ganglion neurons contributes to the development of bone cancer pain in a rat model. ( Cai, J; Fang, D; Han, JS; Liu, M; Wan, Y; Xing, GG; Zheng, Q, 2013)
" Cisplatin produces a cumulative toxic effect on peripheral nerves, and 30-40% of cancer patients receiving this agent experience pain."1.38Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. ( Harding-Rose, C; Khasabov, S; Khasabova, IA; Paz, J; Seybold, VS; Simone, DA, 2012)
"Inflammatory hyperalgesia was measured following intraplantar injection of carrageenan."1.35Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. ( Alexander, SP; Barrett, DA; Bennett, AJ; Chapman, V; Garle, MJ; Jhaveri, MD; Kendall, DA; Patel, A; Richardson, D; Robinson, I; Sagar, DR; Sun, Y, 2008)
"Diabetes caused significant hyperalgesia during these tests."1.35URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats. ( Hasanein, P; Keshavarz, M; Parviz, M; Roohbakhsh, A, 2009)
" Oral dosing with URB597 achieved significant, albeit transient, drug levels in plasma, inhibited brain FAAH activity, and elevated spinal cord anandamide content."1.34The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. ( Calignano, A; Compton, TR; Duranti, A; La Rana, G; Loverme, J; Mor, M; Parrott, J; Piomelli, D; Russo, R; Tarzia, G; Tontini, A, 2007)
"N-arachidonoylserotonin (AA-5-HT, 1a) is an inhibitor of fatty acid amide hydrolase (FAAH) that acts also as an antagonist of transient receptor potential vanilloid-type 1 (TRPV1) channels and is analgesic in rodents."1.34New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. ( Cascio, MG; de Novellis, V; De Petrocellis, L; Di Marzo, V; Maione, S; Morera, E; Nalli, M; Ortar, G; Rossi, F; Schiano-Moriello, A; Woodward, DF, 2007)
"Carbamazepine (100 mg/kg) was weakly effective against all the responses."1.31Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain. ( Field, MJ; Gonzalez, MI; Hughes, J; Singh, L, 2000)

Research

Studies (44)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (25.00)29.6817
2010's29 (65.91)24.3611
2020's4 (9.09)2.80

Authors

AuthorsStudies
Greco, R1
Demartini, C1
Francavilla, M1
Zanaboni, AM1
Tassorelli, C1
Crivelaro do Nascimento, G1
Ferrari, DP1
Guimaraes, FS1
Del Bel, EA1
Bortolanza, M1
Ferreira-Junior, NC1
Zhang, F1
Liu, S1
Jin, L1
Tang, L1
Zhao, X1
Yang, T1
Wang, Y1
Huo, B1
Liu, R1
Li, H1
Lu, R1
Cui, SS1
Wang, XX1
Chen, L1
Liu, F1
Gao, J1
Wang, W1
Uhelski, ML1
Gupta, K1
Simone, DA3
Slivicki, RA2
Saberi, SA1
Iyer, V1
Vemuri, VK1
Makriyannis, A1
Hohmann, AG3
Xu, Z1
Mali, SS1
Starowicz, K2
Makuch, W2
Korostynski, M1
Malek, N2
Slezak, M1
Zychowska, M1
Petrosino, S2
De Petrocellis, L2
Cristino, L1
Przewlocka, B2
Di Marzo, V4
Khasabova, IA2
Holman, M1
Morse, T1
Burlakova, N1
Coicou, L1
Harding-Rose, C2
Seybold, VS2
Niphakis, MJ3
Cognetta, AB1
Chang, JW1
Buczynski, MW1
Parsons, LH1
Byrne, F1
Burston, JJ1
Chapman, V2
Cravatt, BF6
Hayashi, H1
Iwata, M1
Tsuchimori, N1
Matsumoto, T1
Lomazzo, E1
Bindila, L1
Remmers, F1
Lerner, R1
Schwitter, C1
Hoheisel, U1
Lutz, B1
Krustev, E1
Reid, A1
McDougall, JJ1
Gilet, M1
Eutamene, H1
Han, H1
Kim, HW1
Bueno, L1
Nasirinezhad, F1
Jergova, S1
Pearson, JP1
Sagen, J1
Cai, J2
Fang, D2
Liu, XD1
Li, S1
Ren, J1
Xing, GG2
Mrugala, M1
Kolosowska, N1
Binkowski, M1
Czaja, M1
Morera, E2
Ignatowska-Jankowska, B1
Wilkerson, JL3
Mustafa, M2
Abdullah, R1
Niphakis, M1
Wiley, JL1
Lichtman, AH5
Nozaki, C1
Markert, A1
Zimmer, A1
Abd-Elsayed, AA1
Ikeda, R1
Jia, Z1
Ling, J1
Zuo, X1
Li, M1
Gu, JG1
Adamson Barnes, NS1
Mitchell, VA2
Kazantzis, NP1
Vaughan, CW2
Grim, TW1
Mustafa, MA1
Abdullah, RA3
Poklis, JL2
Dewey, WL1
Akbarali, H1
Banks, ML1
Wise, LE1
Ghosh, S1
Cabrera, R1
Maldonado, RL1
Jhaveri, MD1
Richardson, D1
Robinson, I1
Garle, MJ1
Patel, A1
Sun, Y1
Sagar, DR1
Bennett, AJ1
Alexander, SP1
Kendall, DA1
Barrett, DA1
Kinsey, SG2
Long, JZ1
O'Neal, ST1
Boger, DL1
Hasanein, P1
Parviz, M1
Keshavarz, M1
Roohbakhsh, A1
Costa, B1
Bettoni, I1
Comelli, F1
Giagnoni, G1
Xu, W1
Wu, Y1
Bi, Y2
Tan, L1
Gan, Y1
Wang, K2
Naidu, PS1
Dudley, DT1
Chen, H1
Su, J1
Cao, X1
Bian, X1
Sasso, O2
Bertorelli, R2
Bandiera, T1
Scarpelli, R1
Colombano, G1
Armirotti, A1
Moreno-Sanz, G2
Reggiani, A2
Piomelli, D4
Khasabov, S1
Paz, J1
Guindon, J1
Lai, Y1
Takacs, SM1
Bradshaw, HB1
Martucci, C1
Realini, N1
Dionisi, M1
Mengatto, L1
Duranti, A2
Tarozzo, G1
Tarzia, G2
Mor, M2
Taylor, BK1
Zheng, Q1
Liu, M1
Wan, Y1
Han, JS1
Passmore, GM1
Selyanko, AA1
Mistry, M1
Al-Qatari, M1
Marsh, SJ1
Matthews, EA1
Dickenson, AH1
Brown, TA1
Burbidge, SA1
Main, M1
Brown, DA1
Dost, R1
Rostock, A1
Rundfeldt, C1
Jayamanne, A1
Greenwood, R1
Aslan, S1
Haller, VL1
Cichewicz, DL1
Welch, SP1
Liberatore, AM1
Schulz, J1
Favre-Guilmard, C1
Pommier, J1
Lannoy, J1
Pawlowski, E1
Barthelemy, MA1
Huchet, M1
Auguet, M1
Chabrier, PE1
Bigg, D1
Russo, R1
Loverme, J1
La Rana, G1
Compton, TR1
Parrott, J1
Tontini, A1
Calignano, A1
Ortar, G1
Cascio, MG1
Rossi, F1
Schiano-Moriello, A1
Nalli, M1
de Novellis, V1
Woodward, DF1
Maione, S1
Gonzalez, MI1
Field, MJ1
Hughes, J1
Singh, L1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Osteoarthritis of the Knee Pain Study Using CBD and THC in Rapidly Dissolvable Sublingual Tablet[NCT04195269]Phase 230 participants (Anticipated)Interventional2020-04-20Recruiting
Genetic, Epigenetic, Psychosocial, and Biological Determinants of Post-surgical Pain After Pectus or Spine Surgery[NCT04031716]600 participants (Anticipated)Interventional2018-07-06Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

44 other studies available for carbamates and Allodynia

ArticleYear
Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine.
    Cells, 2021, 09-26, Volume: 10, Issue:10

    Topics: Animals; Behavior, Animal; Carbamates; Disease Models, Animal; Endocannabinoids; Hyperalgesia; Male;

2021
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
    Neuropharmacology, 2020, Volume: 163

    Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox

2020
Antinociceptive Efficacy of Retigabine and Flupirtine for Gout Arthritis Pain.
    Pharmacology, 2020, Volume: 105, Issue:7-8

    Topics: Aminopyridines; Analgesics; Animals; Arthritis, Experimental; Arthritis, Gouty; Behavior, Animal; Ca

2020
Astrocytic c-Jun N-terminal kinase-histone deacetylase-2 cascade contributes to glutamate transporter-1 decrease and mechanical allodynia following peripheral nerve injury in rats.
    Brain research bulletin, 2021, Volume: 175

    Topics: Animals; Anthracenes; Astrocytes; Carbamates; Cells, Cultured; Etanercept; Excitatory Amino Acid Tra

2021
Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis.
    Pain, 2017, Volume: 158, Issue:9

    Topics: Anemia, Sickle Cell; Animals; Arachidonic Acids; Benzamides; Carbamates; Disease Models, Animal; End

2017
Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
    The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:3

    Topics: Amidohydrolases; Analgesics, Opioid; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides;

2018
Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor
    Pharmacological research, 2019, Volume: 142

    Topics: Amidohydrolases; Analgesics; Animals; Antineoplastic Agents; Benzamides; Benzoxazines; Brain; Cannab

2019
Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Amides; Amidohydrolases; Analgesia; Animals; Arachidonate 15-Lipoxygenase; Arachidonic Acids; Benzam

2013
Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain.
    Neurobiology of disease, 2013, Volume: 58

    Topics: Animals; Arachidonic Acids; Benzamides; Brain Neoplasms; Cannabinoid Receptor Antagonists; Carbamate

2013
Evaluation of NHS carbamates as a potent and selective class of endocannabinoid hydrolase inhibitors.
    ACS chemical neuroscience, 2013, Sep-18, Volume: 4, Issue:9

    Topics: Amidohydrolases; Animals; Blood Glucose; Brain; Carbamates; Diabetes Mellitus, Type 2; Diabetic Neur

2013
Activation of peripheral KCNQ channels attenuates inflammatory pain.
    Molecular pain, 2014, Feb-21, Volume: 10

    Topics: Animals; Anthracenes; Anticonvulsants; Benzamides; Carbamates; Disease Models, Animal; Electric Stim

2014
Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Volume: 40, Issue:2

    Topics: Amidohydrolases; Analgesics, Non-Narcotic; Animals; Anxiety; Benzamides; Benzodioxoles; Brain; Carba

2015
Tapping into the endocannabinoid system to ameliorate acute inflammatory flares and associated pain in mouse knee joints.
    Arthritis research & therapy, 2014, Sep-27, Volume: 16, Issue:5

    Topics: Acute Disease; Amidohydrolases; Animals; Arthralgia; Benzamides; Carbamates; Carrageenan; Endocannab

2014
Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation.
    Neurogastroenterology and motility, 2014, Volume: 26, Issue:12

    Topics: Animals; Benzamides; Carbamates; Colon; Disease Models, Animal; Female; Hyperalgesia; Inflammation;

2014
Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
    Neuropharmacology, 2015, Volume: 95

    Topics: Amidohydrolases; Amines; Analgesics; Animals; Benzamides; Carbamates; Cyclohexanecarboxylic Acids; D

2015
Suppression of KCNQ/M (Kv7) potassium channels in the spinal cord contributes to the sensitization of dorsal horn WDR neurons and pain hypersensitivity in a rat model of bone cancer pain.
    Oncology reports, 2015, Volume: 33, Issue:3

    Topics: Acetylcholine; Animals; Anthracenes; Bone Neoplasms; Carbamates; Disease Models, Animal; Female; Hyp

2015
A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
    Pain, 2015, Volume: 156, Issue:5

    Topics: Activating Transcription Factor 3; Amidohydrolases; Anilides; Animals; Arachidonic Acids; Benzamides

2015
Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.
    The Journal of pharmacology and experimental therapeutics, 2015, Volume: 353, Issue:2

    Topics: Analgesics; Animals; Benzodioxoles; Biomimetic Materials; Brain; Cannabinoids; Carbamates; Constrict

2015
Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015, Volume: 25, Issue:8

    Topics: Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Benzamides; Cannabinoid Receptor Antagonist

2015
KCNQ channels in nociceptive cold-sensing trigeminal ganglion neurons as therapeutic targets for treating orofacial cold hyperalgesia.
    Molecular pain, 2015, Jul-31, Volume: 11

    Topics: Action Potentials; Animals; Carbamates; Chronic Disease; Cold Temperature; Constriction; Disease Mod

2015
Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model.
    British journal of pharmacology, 2016, Volume: 173, Issue:1

    Topics: Amidohydrolases; Animals; Benzamides; Benzodioxoles; Benzoxazines; Carbamates; Disease Models, Anima

2016
The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
    The Journal of pharmacology and experimental therapeutics, 2016, Volume: 357, Issue:1

    Topics: Analgesics, Opioid; Animals; Arachidonic Acids; Behavior, Animal; Carbamates; Constriction, Patholog

2016
The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
    Neuropharmacology, 2017, 03-01, Volume: 114

    Topics: Acetamides; Analgesics; Analgesics, Opioid; Animals; Arachidonic Acid; Arachidonic Acids; Carbamates

2017
Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain.
    Neuropharmacology, 2008, Volume: 55, Issue:1

    Topics: Amides; Amidohydrolases; Animals; Benzamides; Cannabinoid Receptor Modulators; Carbamates; Carrageen

2008
Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
    The Journal of pharmacology and experimental therapeutics, 2009, Volume: 330, Issue:3

    Topics: Amidohydrolases; Analgesics, Non-Narcotic; Animals; Arachidonic Acids; Benzamides; Benzodioxoles; Ca

2009
URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats.
    Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:6

    Topics: Amidohydrolases; Animals; Benzamides; Blood Glucose; Body Weight; Cannabinoid Receptor Modulators; C

2009
The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice.
    Pharmacological research, 2010, Volume: 61, Issue:6

    Topics: Amidohydrolases; Analgesics; Animals; Anti-Inflammatory Agents; Arachidonic Acids; Benzamides; Capsa

2010
Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.
    Molecular pain, 2010, Aug-27, Volume: 6

    Topics: Analgesia; Animals; Anthracenes; Anticonvulsants; Carbamates; Feeding Behavior; Freund's Adjuvant; H

2010
Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.
    Pharmacology, biochemistry, and behavior, 2011, Volume: 99, Issue:4

    Topics: Amidohydrolases; Animals; Arthritis, Experimental; Benzamides; Camphanes; Carbamates; Foot; Genotype

2011
Visceral hyperalgesia induced by forebrain-specific suppression of native Kv7/KCNQ/M-current in mice.
    Molecular pain, 2011, Oct-26, Volume: 7

    Topics: Animals; Anthracenes; Capsaicin; Carbamates; Hyperalgesia; KCNQ2 Potassium Channel; Magnesium Sulfat

2011
Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
    Pharmacological research, 2012, Volume: 65, Issue:5

    Topics: Amidohydrolases; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experiment

2012
Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2012, May-16, Volume: 32, Issue:20

    Topics: Activating Transcription Factor 3; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; Ca

2012
Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following c
    Pharmacological research, 2013, Volume: 67, Issue:1

    Topics: Amidohydrolases; Analgesics; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides; Benzodio

2013
Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
    Pain, 2013, Volume: 154, Issue:3

    Topics: Amides; Amidohydrolases; Analgesics; Animals; Burns; Carbamates; Carrageenan; Dose-Response Relation

2013
N-acylethanolamine acid amidase (NAAA), a new path to unleash PPAR-mediated analgesia.
    Pain, 2013, Volume: 154, Issue:3

    Topics: Amides; Amidohydrolases; Analgesics; Animals; Carbamates; Endocannabinoids; Enzyme Inhibitors; Ethan

2013
Suppression of KCNQ/M (Kv7) potassium channels in dorsal root ganglion neurons contributes to the development of bone cancer pain in a rat model.
    Pain, 2013, Volume: 154, Issue:3

    Topics: Animals; Anthracenes; Bone Neoplasms; Carbamates; Carcinoma; Down-Regulation; Female; Ganglia, Spina

2013
KCNQ/M currents in sensory neurons: significance for pain therapy.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Aug-06, Volume: 23, Issue:18

    Topics: Animals; Anthracenes; Anura; Carbamates; Cells, Cultured; CHO Cells; Cricetinae; Disease Models, Ani

2003
The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
    Naunyn-Schmiedeberg's archives of pharmacology, 2004, Volume: 369, Issue:4

    Topics: Acute Disease; Amines; Analgesics, Opioid; Animals; Carbamates; Cyclohexanecarboxylic Acids; Disease

2004
Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.
    British journal of pharmacology, 2006, Volume: 147, Issue:3

    Topics: Amidohydrolases; Animals; Benzamides; Carbamates; Chronic Disease; Disease Models, Animal; Enzyme In

2006
Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
    European journal of pharmacology, 2006, Sep-28, Volume: 546, Issue:1-3

    Topics: Acetaminophen; Amides; Analgesics; Animals; Arachidonic Acids; Benzamides; Benzoquinones; Camphanes;

2006
Butyl 2-(4-[1.1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain.
    Bioorganic & medicinal chemistry letters, 2007, Mar-15, Volume: 17, Issue:6

    Topics: Animals; Batrachotoxins; Binding, Competitive; Carbamates; Carrageenan; Humans; Hyperalgesia; Imidaz

2007
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 322, Issue:1

    Topics: Administration, Oral; Amidohydrolases; Analgesics; Animals; Benzamides; Capillary Permeability; Carb

2007
New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.
    Journal of medicinal chemistry, 2007, Dec-27, Volume: 50, Issue:26

    Topics: Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Biphenyl Compounds; Brain; Calcium; Carbama

2007
Evaluation of selective NK(1) receptor antagonist CI-1021 in animal models of inflammatory and neuropathic pain.
    The Journal of pharmacology and experimental therapeutics, 2000, Volume: 294, Issue:2

    Topics: Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Behavior, Animal; Benzofurans; Ca

2000